Viela Bio   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Gaithersburg MD United States (2017)
Status: Acquired by Horizon Therapeutics, LLC (2021) → now Amgen (2022)

Organization Overview

First Clinical Trial
2018
NCT03621605
First Marketed Drug
2020
inebilizumab (Uplizna)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Viela Bio | VIELA BIO

Active Ingredients

Marketed Drugs (1)

inebilizumab (Uplizna) (2020)

Drugs in Phase 3 Trials (1)

inebilizumab (Uplizna) (3 trials)

Drugs in Phase 2 Trials (3)

belatacept (nujolix) (1 trial)

medi7734 (3 trials)

vib4920 (4 trials)

Drugs in Phase 1 Trials (2)

vib1116 (1 trial)

vib9600 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Death (Phase 2)

Dermatomyositis (Phase 1)

Immunoglobulin G4-Related Disease (Phase 3)

Lung Injury (Phase 1)

Lupus Erythematosus, Cutaneous (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Muscle Weakness (Phase 3)

Myasthenia Gravis (Phase 3)

Polymyositis (Phase 1)

Respiratory Distress Syndrome (Phase 1)

Scleroderma, Diffuse (Phase 1)

Scleroderma, Systemic (Phase 1)

Sclerosis (Phase 1)

Sjogren's Syndrome (Phase 2)

Syndrome (Phase 2)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 6